# Program A03 Phase 2 Baseline

## Program

Program A03 - Scientific Content Population: SSRIs.

## Phase

Phase 2 - Drug Portfolio Definition.

## Mission

MISSION A03-020 - PHASE_2_BASELINE.

## Baseline Status

Published as metadata-only baseline.

## Baseline Scope

This baseline consolidates:

- Drug Registry;
- Editorial Registry;
- Metadata Registry;
- Source Registry;
- Binding Registry;
- Master Registry;
- Directory Structure;
- Templates;
- Editorial Framework;
- Traceability Framework;
- Quality Assurance;
- Schemas;
- Indexes;
- Manifests.

## Baseline Evidence

- `docs/QA_RESULTS.json`
- `docs/QA_VALIDATION_REPORT.md`
- `KnowledgeBase/SSRIs/Manifest/PHASE2_BASELINE.json`
- `KnowledgeBase/SSRIs/Manifest/PHASE2_STATUS.json`
- `KnowledgeBase/SSRIs/Manifest/PHASE2_GATE_STATUS.json`

## QA Result

QA passed with 0 critical issues.

## Gate Result

All 8 Phase 2 gates are approved.

## Original Release Scope

At the time of A03-020, the baseline authorized the next transitional mission:

```text
A03-021 - DRUG_IDENTIFICATION
```

## Superseding Decision

ADR 0045 refactored Phase 3. A03-021 was completed as:

```text
A03-021 - SCIENTIFIC_DRUG_PROFILE_INITIALIZATION
```

The current next mission is:

```text
A03-022 - MECHANISM_OF_ACTION_MODELING
```

This does not authorize broad scientific population, therapeutic recommendations, prescription or runtime consumption.

## Explicit Non-Actions

This mission did not:

- create Drug Profiles;
- interpret literature;
- consume Scientific Corpus content;
- register mechanisms;
- register receptors;
- register neurotransmitters;
- register PK or PD;
- register doses;
- register indications;
- register contraindications;
- register adverse effects;
- register safety content;
- register interactions;
- register guidelines;
- register evidence;
- create runtime objects;
- create Knowledge Graph entries.

## Declaration Final

Program A03 Phase 2 is baselined as metadata-only infrastructure. Phase 3 now proceeds under ADR 0045 and remains governed by source-level traceability, editorial review and explicit non-prescription constraints.
